All In Biotech

Drug Trial Radar · NCT05400265

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor

Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Jul 26, 2022

Primary completion

Aug 31, 2023

Study completion Jan 31, 2024

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors.

Conditions

  • Adult Solid Tumor

Interventions

  • HLX26Drug

    Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

  • HLX10Drug

    Humanized Anti-Programmed Death-1 Monoclonal Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: from day1 to day 21
  2. MTDTime frame: from day1 to day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.